Stockscreener 앱 받기
87.84
1.82%
-1.69
전일 마감가:
$89.53
열려 있는:
$89.5
하루 거래량:
1.02M
Relative Volume:
0.22
시가총액:
$33.14B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
37.57
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+0.64%
1개월 성능:
-4.80%
6개월 성능:
+33.31%
1년 성능:
+28.89%
1일 변동 폭
$87.36
$90.05
1주일 범위
$87.17
$90.39
52주 변동 폭
$54.11
$92.59
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
87.83 | 33.79B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
103.71 | 179.42B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
89.08 | 116.11B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.30 | 105.52B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.17 | 65.10B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.41 | 51.17B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - ACCESS Newswire
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration - TradingView
Dexcom stock holds near its yearly high after Q2 growth - AD HOC NEWS
Dexcom stock heads into the open after Nasdaq gains 0.45 percent - AD HOC NEWS
Dexcom Inc. stock gains on strong Q2 2026 growth and solid diabetes-tech momentum - AD HOC NEWS
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance Singapore
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings and Promising Growth in the Medical Device Sector - DirectorsTalk Interviews
Dexcom stock heads into the open after a 1.61 percent gain - AD HOC NEWS
Dexcom Inc. stock gains on leadership change and strong recent performance - AD HOC NEWS
Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets - AD HOC NEWS
What Has Put DexCom (DXCM) Back in Focus? - Kalkine Media
DexCom Inc. stock outperforms competitors on strong trading day - marketwatch.com
DXCM Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
TD Cowen reiterates Buy rating on DexCom, $95 price target - TradingView
Dexcom Inc. stock gains as insider sales and valuation come into focus - AD HOC NEWS
Dexcom stock heads into the open after a 0.68% Nasdaq gain - AD HOC NEWS
Dexcom Inc. stock edges higher as Truist Securities reiterates Buy rating - AD HOC NEWS
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating - marketscreener.com
Dexcom stock heads into the open after a 1.0% gain - AD HOC NEWS
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing - marketscreener.com
Dexcom (NASDAQ: DXCM) director’s trust sells 8,089 shares in preset plan - Stock Titan
Dexcom (NASDAQ: DXCM) legal chief sells shares, keeps 99,885-share stake - Stock Titan
DexCom Inc (DXCM): GF Score of 95 Signals Strong Outperformance Potential - GuruFocus
Dexcom gives CFO Jereme Sylvain expanded role - MedTech Dive
Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026 - marketscreener.com
Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Yahoo Finance
Dexcom (DXCM) CFO trades stock under preset plan - Stock Titan
Dexcom (DXCM) Promotes CFO Jereme Sylvain to Chief Operating Off - GuruFocus
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom appoints Glenn Boehnlein to board of directors - The Globe and Mail
DexCom (DXCM) Expands Board to 13 Directors with Appointment of Glenn S. Boehnlein - GuruFocus
Dexcom stock heads into the open after a 0.8% Nasdaq pullback - ad-hoc-news.de
Dexcom Appoints Glenn Boehnlein to Board of Directors - BioSpace
DexCom Expands Board with Glenn Boehnlein Appointment and Details Compensation Plan - Kalkine Media
DexCom, Inc. Announces Appointment of Glenn S. Boehnlein as Director, Member of Operations & Innovation Committee and Audit Committee, Effective September 10, 2026 - marketscreener.com
Dexcom (NASDAQ: DXCM) director gets 5,841-unit stock grant vesting over 3 years - Stock Titan
Dexcom (DXCM) director discloses 42-share trust stake - Stock Titan
DexCom appoints Glenn S. Boehnlein to Board and committees - TradingView
Dexcom (NASDAQ: DXCM) officer lines up six‑figure stock sale - Stock Titan
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Dexcom Inc. stock steadies near mid-range as conference outlines growth plan - ad-hoc-news.de
DexCom expects CONNECT study on type 2 diabetes to be published soon in a major journal. - Pluang
Dexcom at Wells Fargo conference: coverage push drives growth plan By Investing.com - Investing.com India
Transcript : DexCom, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:00 AM - marketscreener.com
DexCom Stock: Is DXCM Underperforming the Healthcare Sector? - webull.com
Dexcom stock heads into the open after a 3.8 percent drop - ad-hoc-news.de
Kakao Healthcare Lends Glucose Monitors to Diabetic Exam Takers - Seoul Economic Daily
DexCom Inc (DXCM) Shares Fall 3.8% -- What GF Score of 95 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Law firm probes DexCom officers for possible br... - Pluang
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AUGUSTINOS NICHOLAS | Director |
Sep 14 '26 |
Sale |
84.02 |
1,550 |
130,231 |
35,832 |
| Brown Michael Jon | EVP Chief Legal Compliance Off |
Sep 15 '26 |
Sale |
84.04 |
1,700 |
142,868 |
99,885 |
0.35%
0.38%
자본화:
|
볼륨(24시간):